Profile data is unavailable for this security.
About the company
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development and commercialization of therapies for debilitating rare and orphan diseases. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. It is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
- Revenue in USD (TTM)186.37m
- Net income in USD-163.42m
- Incorporated2018
- Employees264.00
- LocationMirum Pharmaceuticals Inc950 Tower Ln Ste 1050FOSTER CITY 94404-4251United StatesUSA
- Phone+1 (650) 667-4085
- Fax+1 (302) 269-3855
- Websitehttps://mirumpharma.com/
Mergers & acquisitions
Acquired company | MIRM:NMQ since announced | Transaction value |
---|---|---|
Travere Therapeutics Inc-Bile Acid Product Portfolio | -0.19% | 445.00m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
AbCellera Biologics Inc | 38.03m | -146.40m | 1.18bn | 586.00 | -- | 1.02 | -- | 31.03 | -0.5062 | -0.5062 | 0.1315 | 3.96 | 0.0251 | -- | 1.10 | 64,890.79 | -9.67 | 6.08 | -10.49 | 6.67 | -- | -- | -384.99 | 24.69 | 7.32 | -- | 0.00 | 0.00 | -92.17 | 33.91 | -192.35 | -- | 70.96 | -- |
MannKind Corp | 198.96m | -11.94m | 1.19bn | 414.00 | -- | -- | -- | 5.97 | -0.0464 | -0.0464 | 0.7087 | -0.9116 | 0.5165 | 2.50 | 12.55 | 480,584.50 | -3.10 | -26.07 | -3.99 | -37.80 | 68.45 | 59.68 | -6.00 | -57.61 | 3.31 | 0.5023 | 1.90 | -- | 99.42 | 48.17 | 86.34 | -- | 160.47 | -- |
Pharvaris NV | 0.00 | -108.52m | 1.22bn | 82.00 | -- | 2.86 | -- | -- | -2.71 | -2.71 | 0.00 | 7.90 | 0.00 | -- | -- | 0.00 | -35.62 | -36.09 | -37.81 | -38.27 | -- | -- | -- | -- | -- | -33.51 | 0.0006 | -- | -- | -- | -32.15 | -- | -- | -- |
Mirum Pharmaceuticals Inc | 186.37m | -163.42m | 1.22bn | 264.00 | -- | 4.86 | -- | 6.53 | -4.08 | -4.08 | 4.56 | 5.32 | 0.3729 | 3.37 | 4.05 | 705,962.10 | -32.70 | -38.93 | -38.55 | -44.88 | 74.76 | -- | -87.68 | -190.71 | 4.19 | -79.67 | 0.552 | -- | 141.85 | -- | -20.45 | -- | 21.81 | -- |
Cullinan Therapeutics Inc | 0.00 | -153.16m | 1.22bn | 85.00 | -- | 2.68 | -- | -- | -3.70 | -3.70 | 0.00 | 10.58 | 0.00 | -- | -- | 0.00 | -29.68 | -12.37 | -31.19 | -12.93 | -- | -- | -- | -1,026.78 | -- | -- | 0.00 | -- | -- | -- | -237.72 | -- | -4.44 | -- |
Scholar Rock Holding Corp | 0.00 | -165.79m | 1.22bn | 150.00 | -- | 5.18 | -- | -- | -1.99 | -1.99 | 0.00 | 2.96 | 0.00 | -- | -- | 0.00 | -49.55 | -38.14 | -55.26 | -44.31 | -- | -- | -- | -647.95 | -- | -- | 0.1817 | -- | -100.00 | -- | -23.26 | -- | -45.61 | -- |
Collegium Pharmaceutical Inc | 566.77m | 48.16m | 1.23bn | 197.00 | 42.52 | 6.12 | 6.21 | 2.16 | 0.8823 | 0.8823 | 12.53 | 6.13 | 0.4891 | 6.10 | 3.13 | 2,876,990.00 | 4.16 | 2.79 | 6.75 | 4.80 | 57.55 | 50.88 | 8.50 | 5.16 | 1.10 | 2.59 | 0.7734 | 0.00 | 22.17 | 15.11 | 292.60 | -- | -54.77 | -- |
Prothena Corporation PLC | 91.37m | -147.03m | 1.23bn | 173.00 | -- | 2.19 | -- | 13.48 | -2.80 | -2.80 | 1.68 | 10.46 | 0.1256 | -- | -- | 528,150.30 | -20.22 | -14.20 | -21.82 | -15.11 | -- | -- | -160.92 | -111.02 | -- | -- | 0.00 | -- | 69.50 | 148.98 | -25.72 | -- | 9.71 | -- |
Pacira Biosciences Inc | 674.98m | 41.96m | 1.27bn | 711.00 | 40.08 | 1.45 | 10.77 | 1.88 | 0.6789 | 0.6789 | 12.33 | 18.72 | 0.4147 | 1.84 | 6.62 | 949,336.10 | 2.58 | 3.35 | 2.79 | 3.98 | 72.64 | 72.63 | 6.22 | 8.57 | 4.17 | 9.85 | 0.3752 | 0.00 | 1.22 | 14.88 | 163.72 | -- | 0.8761 | -- |
Belite Bio Inc (ADR) | 0.00 | -31.63m | 1.29bn | 20.00 | -- | 13.93 | -- | -- | -1.24 | -1.24 | 0.00 | 3.10 | 0.00 | -- | -- | 0.00 | -45.54 | -- | -47.50 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -150.09 | -- | -- | -- |
Ironwood Pharmaceuticals, Inc. | 442.74m | -1.00bn | 1.29bn | 267.00 | -- | -- | -- | 2.92 | -6.51 | -6.51 | 2.59 | -2.21 | 0.5634 | -- | 3.62 | 1,658,184.00 | -131.28 | -4.54 | -162.45 | -5.20 | -- | -- | -233.00 | -7.81 | -- | 63.79 | 1.98 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
Gyre Therapeutics Inc | 0.00 | -44.24m | 1.29bn | 7.00 | -- | -- | -- | -- | -20.60 | -20.60 | 0.00 | 1.39 | 0.00 | -- | -- | 0.00 | -215.90 | -58.25 | -235.61 | -72.12 | -- | -- | -- | -817.06 | -- | -- | 0.00 | -- | -89.18 | -4.85 | 90.63 | -- | -- | -- |
Spyre Therapeutics Inc | 886.00k | -338.79m | 1.31bn | 30.00 | -- | -- | -- | 1,478.04 | -75.04 | -75.04 | 0.1285 | 7.45 | 0.0043 | -- | 4.73 | 29,533.33 | -164.06 | -101.87 | -184.94 | -118.83 | -- | -- | -38,238.15 | -2,949.59 | -- | -- | 0.00 | -- | -61.96 | -25.61 | -304.21 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
BVF Partners LPas of 31 Dec 2023 | 4.37m | 9.38% |
Eventide Asset Management LLCas of 31 Dec 2023 | 2.66m | 5.71% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 2.40m | 5.14% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 2.26m | 4.86% |
Janus Henderson Investors US LLCas of 31 Dec 2023 | 2.05m | 4.39% |
Cadian Capital Management LPas of 31 Dec 2023 | 1.93m | 4.15% |
Rock Springs Capital Management LPas of 31 Dec 2023 | 1.85m | 3.97% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 1.73m | 3.72% |
Citadel Advisors LLCas of 31 Dec 2023 | 1.39m | 2.99% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 1.15m | 2.47% |